Venture Map · Round
Vaxdyn — Series A · €11M
Announced 2026-09-07 · Dos Hermanas · Biotech / vaccines
The Seville-area biotech raised €11M to take K-VAX, its vaccine against multidrug-resistant Klebsiella pneumoniae and Acinetobacter baumannii, into a Phase 1 trial. Biovance Capital led with €4M and Arcano Partners' Impacto Andalucía fund put in €3.6M, complemented by €3.2M of non-dilutive EIC Accelerator money.
RoundSeries A
Amount€11M
LeadBiovance Capital
Date2026-09-07
CityDos Hermanas
SectorBiotech / vaccines
